Table of Content

Chapter 1. Executive summary

1.1. Market scope and segmentation
1.2. Key questions answered
1.3. Executive summary

Chapter 2. Global precision medicine market – overview

2.1. Global market overview - historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), geography-wise market revenue (USD Bn), and market attractiveness analysis
2.2. Global market drivers
2.3. Global market trends
2.4. Global market challenges
2.5. Value chain analysis
2.6. Porter’s five forces analysis
2.7. Market segmentation based on ecosystem players (pharmaceutical and biotechnology companies, clinical laboratories, diagnostic companies, and healthcare IT/big data companies) - historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), and key market observations
2.8. Market segmentation based on therapeutics (cancer, cardiovascular diseases, central nervous system [CNS] disorders, psychiatric disorders, respiratory diseases, infectious diseases, and others) - historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), and key market observations
2.9. Market segmentation based on technology (big data analytics, bioinformatics, genomics, pharmacogenomics, companion diagnostics, epigenetics, and others) - historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), and key market observations

Chapter 3. North America precision medicine market

3.1. Regional market overview - historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), and key market observations
3.2. Market segmentation based on ecosystem players (pharmaceutical and biotechnology companies, clinical laboratories, diagnostic companies, and healthcare IT/big data companies) - historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), and key market observations
3.3. Market segmentation based on therapeutics (cancer, cardiovascular diseases, central nervous system [CNS] disorders, psychiatric disorders, respiratory diseases, infectious diseases, and others) - historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), and key market observations
3.4. Market segmentation based on technology (big data analytics, bioinformatics, genomics, pharmacogenomics, companion diagnostics, epigenetics, and others) - historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), and key market observations

Chapter 4. Europe precision medicine market

4.1. Regional market overview - historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), and key market observations
4.2. Market segmentation based on ecosystem players (pharmaceutical and biotechnology companies, clinical laboratories, diagnostic companies, and healthcare IT/big data companies) - historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), and key market observations
4.3. Market segmentation based on therapeutics (cancer, cardiovascular diseases, central nervous system [CNS] disorders, psychiatric disorders, respiratory diseases, infectious diseases, and others) - historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), and key market observations
4.4. Market segmentation based on technology (big data analytics, bioinformatics, genomics, pharmacogenomics, companion diagnostics, epigenetics, and others) - historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), and key market observations

Chapter 5. Asia-Pacific precision medicine market

5.1. Regional market overview - historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), and key market observations
5.2. Market segmentation based on ecosystem players (pharmaceutical and biotechnology companies, clinical laboratories, diagnostic companies, and healthcare IT/big data companies) - historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), and key market observations
5.3. Market segmentation based on therapeutics (cancer, cardiovascular diseases, central nervous system [CNS] disorders, psychiatric disorders, respiratory diseases, infectious diseases, and others) - historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), and key market observations
5.4. Market segmentation based on technology (big data analytics, bioinformatics, genomics, pharmacogenomics, companion diagnostics, epigenetics, and others) - historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), and key market observations

Chapter 6. Latin America precision medicine market

6.1. Regional market overview - historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), and key market observations
6.2. Market segmentation based on ecosystem players (pharmaceutical and biotechnology companies, clinical laboratories, diagnostic companies, and healthcare IT/big data companies) - historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), and key market observations
6.3. Market segmentation based on therapeutics (cancer, cardiovascular diseases, central nervous system [CNS] disorders, psychiatric disorders, respiratory diseases, infectious diseases, and others) - historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), and key market observations
6.4. Market segmentation based on technology (big data analytics, bioinformatics, genomics, pharmacogenomics, companion diagnostics, epigenetics, and others) - historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), and key market observations

Chapter 7. The Middle East and Africa precision medicine market

7.1. Regional market overview - historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), and key market observations
7.2. Market segmentation based on ecosystem players (pharmaceutical and biotechnology companies, clinical laboratories, diagnostic companies, and healthcare IT/big data companies) - historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), and key market observations
7.3. Market segmentation based on therapeutics (cancer, cardiovascular diseases, central nervous system [CNS] disorders, psychiatric disorders, respiratory diseases, infectious diseases, and others) - historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), and key market observations
7.4. Market segmentation based on technology (big data analytics, bioinformatics, genomics, pharmacogenomics, companion diagnostics, epigenetics, and others) - historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), and key market observations

Chapter 8. Competitive landscape
8.1. Abbott Laboratories
8.1.a. Company snapshot
8.1.b. Products/services
8.1.c. Major initiatives/highlights
8.1.d. Growth strategy
8.1.e. Key people
8.1.f. Global presence
Note: Similar information areas will be covered for the remaining competitors:
8.2. GE Healthcare
8.3. GlaxoSmithKline
8.4. Johnson & Johnson
8.5. Pfizer
8.6. Randox Laboratories
8.7. Almac Group
8.8. Novartis AG
8.9. Teva Pharmaceutical Industries Ltd.
8.10. Quest Diagnostics

Chapter 9 Conclusion
9.1. Future outlook

Appendix
• List of tables
• Research methodology
• Assumptions
• About Netscribes Inc.